CoChat
Sign Up
Cited by 91

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population

van Zeventer, Isabelle A., de Graaf, Aniek O., Salzbrunn, Jonas B., Nolte, Ilja M., Kamphuis, Priscilla, Dinmohamed, Avinash, van der Reijden, Bert A., Schuringa, Jan Jacob, Jansen, Joop H., Huls, Gerwin·2023·Cancer Cell
DOI 10.1016/j.ccell.2023.04.006
Open this paper in CoChat — free account

Abstract

Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for DNMT3A and TP53 increase only marginally, independent of cytosis or cytopenia. Nevertheless, large differences are observed between individuals carrying the same mutation, indicative of modulation by non-mutation-related factors. Clonal expansion is not dependent on classical cancer risk factors (e.g., smoking). Risk for incident myeloid malignancy diagnosis is highest for JAK2, spliceosome, or TP53 mutations and absent for DNMT3A, and it is mostly preceded by cytosis or cytopenia. The results provide important insight into high-risk evolutionary patterns to guide monitoring of "CHIP" and "CCUS."

Overview

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2023.04.006

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 23 references

Research works printed but not linked: 37

  1. Steensma, 2015, Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes, Blood, 126, 9, 10.1182/blood-2015-03-631747 · DOI · Paper page
  2. Bejar, 2017, CHIP, ICUS, CCUS and other four-letter words, Leukemia, 31, 1869, 10.1038/leu.2017.181 · DOI
  3. Malcovati, 2017, Clinical significance of somatic mutation in unexplained blood cytopenia, Blood, 129, 3371, 10.1182/blood-2017-01-763425 · DOI
  4. Kwok, 2015, MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance, Blood, 126, 2355, 10.1182/blood-2015-08-667063 · DOI
  5. Hansen, 2016, Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes, Am. J. Hematol., 91, 1234, 10.1002/ajh.24554 · DOI
  6. Khoury, 2022, The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms, Leukemia, 36, 1703, 10.1038/s41375-022-01613-1 · DOI · Paper page
  7. Arber, 2022, International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data, Blood, 140, 1200, 10.1182/blood.2022015850 · DOI · Paper page
  8. van Zeventer, 2021, Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years, Blood Adv., 5, 2115, 10.1182/bloodadvances.2020004062 · DOI
  9. Coombs, 2017, Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes, Cell Stem Cell, 21, 374, 10.1016/j.stem.2017.07.010 · DOI · Paper page
  10. Bolton, 2020, Cancer therapy shapes the fitness landscape of clonal hematopoiesis, Nat. Genet., 52, 1219, 10.1038/s41588-020-00710-0 · DOI · Paper page
  11. Dawoud, 2020, Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking, Leukemia, 34, 2660, 10.1038/s41375-020-0896-8 · DOI
  12. Jolly, 2018, Timing somatic events in the evolution of cancer, Genome Biol., 19, 95, 10.1186/s13059-018-1476-3 · DOI
  13. Robertson, 2022, Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects, Nat. Med., 28, 1439, 10.1038/s41591-022-01883-3 · DOI · Paper page
  14. van Zeventer, 2020, Mutational spectrum and dynamics of clonal hematopoiesis in anemia of older individuals, Blood, 135, 1161
  15. Kamphuis, 2023, Abnormal platelet counts and clonal hematopoiesis in the general population, Hemasphere, 7, e821, 10.1097/HS9.0000000000000821 · DOI
  16. Kar, 2022, Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis, Nat. Genet., 54, 1155, 10.1038/s41588-022-01121-z · DOI · Paper page
  17. Niroula, 2021, Distinction of lymphoid and myeloid clonal hematopoiesis, Nat. Med., 27, 1921, 10.1038/s41591-021-01521-4 · DOI
  18. Zink, 2017, Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly, Blood, 130, 742, 10.1182/blood-2017-02-769869 · DOI · Paper page
  19. Jongen-Lavrencic, 2018, Molecular minimal residual disease in acute myeloid leukemia, N. Engl. J. Med., 378, 1189, 10.1056/NEJMoa1716863 · DOI
  20. Graubert, 2011, Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes, Nat. Genet., 44, 53, 10.1038/ng.1031 · DOI
  21. Papaemmanuil, 2013, Clinical and biological implications of driver mutations in myelodysplastic syndromes, Blood, 122, 3616, 10.1182/blood-2013-08-518886 · DOI · Paper page
  22. van Zeventer, 2022, Monocytosis and its association with clonal hematopoiesis in community-dwelling individuals, Blood Adv., 6, 4174, 10.1182/bloodadvances.2021006755 · DOI
  23. Gallì, 2021, Relationship between clone metrics and clinical outcome in clonal cytopenia, Blood, 138, 965, 10.1182/blood.2021011323 · DOI
  24. Saiki, 2021, Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis, Nat. Med., 27, 1239, 10.1038/s41591-021-01411-9 · DOI
  25. Cordua, 2019, Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population, Blood, 134, 469, 10.1182/blood.2019001113 · DOI
  26. Young, 2013, Current concepts in the pathophysiology and treatment of aplastic anemia, Hematology. Am. Soc. Hematol. Educ. Program, 2013, 76, 10.1182/asheducation-2013.1.76 · DOI
  27. Ogawa, 2016, Clonal hematopoiesis in acquired aplastic anemia, Blood, 128, 337, 10.1182/blood-2016-01-636381 · DOI
  28. Kristinsson, 2011, Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes, J. Clin. Oncol., 29, 2897, 10.1200/JCO.2011.34.8540 · DOI · Paper page
  29. Fleischman, 2011, TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms, Blood, 118, 6392, 10.1182/blood-2011-04-348144 · DOI
  30. Silver, 2021, Germline risk of clonal haematopoiesis, Nat. Rev. Genet., 22, 603, 10.1038/s41576-021-00356-6 · DOI
  31. Gao, 2021, Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis, Nat. Commun., 12, 338, 10.1038/s41467-020-20565-7 · DOI
  32. Cargo, 2015, Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression, Blood, 126, 2362, 10.1182/blood-2015-08-663237 · DOI
  33. Scholtens, 2015, Cohort Profile: LifeLines, a three-generation cohort study and biobank, Int. J. Epidemiol., 44, 1172, 10.1093/ije/dyu229 · DOI · Paper page
  34. Klijs, 2015, Representativeness of the LifeLines cohort study, PLoS One, 10, e0137203, 10.1371/journal.pone.0137203 · DOI
  35. Slagter, 2013, Associations between smoking, components of metabolic syndrome and lipoprotein particle size, BMC Med., 11, 195, 10.1186/1741-7015-11-195 · DOI
  36. Siebelink, 2011, Self-reported energy intake by FFQ compared with actual energy intake to maintain body weight in 516 adults, Br. J. Nutr., 106, 274, 10.1017/S0007114511000067 · DOI
  37. Schouten, 1993, Completeness of cancer registration in Limburg, The Netherlands, Int. J. Epidemiol., 22, 369, 10.1093/ije/22.3.369 · DOI

Cited by

Metadata

Authors
van Zeventer, I. A., de Graaf, A. O., Salzbrunn, J. B., Nolte, I. M., Kamphuis, P., Dinmohamed, A., van der Reijden, B. A., Schuringa, J. J., Jansen, J. H., & Huls, G.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2023-06
Volume
41
Issue
6
Pages
1017-1031.e4
ISSN
1535-6108
DOI
10.1016/j.ccell.2023.04.006
Cited by
91
References
23
Language
en
Licence
Funders
  • European Union
  • Rijksuniversiteit Groningen
  • Horizon 2020 Framework Programme
  • Ministerie van Volksgezondheid, Welzijn en Sport
  • Ministerie van Economische Zaken
  • Horizon 2020 (634789)
  • Stanford Genome Technology Center

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review